STOCK TITAN
  1. Home
  2. News
  3. UCBJY

UCB SA - UCBJY STOCK NEWS

Welcome to our dedicated news page for UCB SA (Ticker: UCBJY), a resource for investors and traders seeking the latest updates and insights on UCB SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect UCB SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of UCB SA's position in the market.

News
Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
Rhea-AI Summary
UCB: Post Hoc Analysis Reveals CIMZIA's Efficacy in RA Patients with High RF Levels
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
Rhea-AI Summary
UCB - New BIMZELX Phase 2b Study Data Shows Sustained Improvements in Ankylosing Spondylitis Patients, Presented at ACR Convergence 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
Rhea-AI Summary
UCB will be presenting results from its portfolio in generalized myasthenia gravis (gMG) at the AANEM annual meeting and the MGFA Scientific Session. The presentations will include data from the MycarinG and RAISE studies, as well as real-world MG data. UCB's rozanolixizumab-noli and zilucoplan have received regulatory approvals for the treatment of gMG in adult patients. UCB will also host a symposium on navigating the new treatment landscape for gMG.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
none
News
NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
Rhea-AI Summary
UCB, a global biopharmaceutical company, announced that a post hoc analysis from the Phase 3 open-label extension study of NAYZILAM showed that the median time to return to full baseline function (RTFBF) after using the nasal spray for seizure clusters was 90 minutes. The analysis revealed that the time to RTFBF was stable over the course of repeated, intermittent use. NAYZILAM is a nasal treatment for seizure clusters in people 12 years of age or older, approved by the FDA in 2019.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
-
News
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Rhea-AI Summary
The US FDA has approved BIMZELX® (bimekizumab-bkzx) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. BIMZELX is the first and only approved psoriasis treatment designed to selectively inhibit two key cytokines driving inflammatory processes – interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
-
News
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
Rhea-AI Summary
UCB receives FDA approval for ZILBRYSQ®, a once-daily subcutaneous treatment for generalized myasthenia gravis (gMG) in adult patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
fda approval
News
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023
Rhea-AI Summary
UCB to present data on bimekizumab in hidradenitis suppurativa at symposium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
News
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
Rhea-AI Summary
UCB announces positive results from Phase 3 bimekizumab studies in hidradenitis suppurativa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
clinical trial
-
News
UCB presents late-breaking posters at Child Neurology Society Meeting
Rhea-AI Summary
The Child Neurology Society Meeting will showcase UCB's research on Dravet syndrome. A retrospective analysis showed that fenfluramine reduced healthcare utilization by 77% in individuals with Dravet syndrome, along with reductions in ER visits, outpatient visits, neurology visits, and inpatient hospitalizations. The survey highlighted challenges in early diagnosis and the importance of patient advocacy groups and online resources. These advancements in understanding and managing Dravet syndrome are positive for UCB.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
News
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
Stock UCBJY logo
UCB SA

OTC:UCBJY

UCBJY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

UCBJY Stock Data

24.24B
119.66M
0%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Belgium
Anderlecht